aTyr Pharma, Inc. Stock News

Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability

NEW YORK , Nov. 26, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline. So what: If you purchased aTyr Pharma common stock during the Class Period yo...

LOS ANGELES , Nov. 26, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). IF YOU SUFFERED A LOSS ON YOUR ATYR INVESTMENTS, CLICK HERE BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSU...

SAN FRANCISCO , Nov. 25, 2025 /PRNewswire/ -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs' rights firm Hagens Berman has been investigating...

BENSALEM, Pa. , Nov. 21, 2025 /PRNewswire/ -- The Law Offices of Howard G.

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext...

LOS ANGELES, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ATYR during the class p...